首页> 美国卫生研究院文献>Asian Journal of Andrology >The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction
【2h】

The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction

机译:LIM激酶2抑制剂和5型磷酸二酯酶抑制剂联合治疗对海绵状神经损伤引起的勃起功能障碍模型中勃起功能的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We aimed to determine whether combination of LIM-kinase 2 inhibitor (LIMK2i) and phosphodiesterase type-5 inhibitor (PDE5i) could restore erectile function through suppressing cavernous fibrosis and improving cavernous apoptosis in a rat model of cavernous nerve crush injury (CNCI). Seventy 12-week-old Sprague–Dawley rats were equally distributed into five groups as follows: (1) sham surgery (Group S), (2) CNCI (Group I), (3) CNCI treated with daily intraperitoneal administration of 10.0 mg kg−1 LIMK2i (Group I + L), (4) daily oral administration of 20.0 mg kg−1 udenafil, PDE5i (Group I + U), and (5) combined administration of 10.0 mg kg−1 LIMK2i and 20.0 mg kg−1 udenafil (Group I + L + U). Rats in Groups I + L, I + U, and I + L + U were treated with respective regimens for 2 weeks after CNCI. At 2 weeks after surgery, erectile response was assessed using electrostimulation. Penile tissues were processed for histological studies and western blot. Group I showed lower intracavernous pressure (ICP)/mean arterial pressure (MAP), lower area under the curve (AUC)/MAP, decreased immunohistochemical staining for alpha-smooth muscle (SM) actin, higher apoptotic index, lower SM/collagen ratio, increased phospho-LIMK2-positive fibroblasts, decreased protein kinase B/endothelial nitric oxide synthase (Akt/eNOS) phosphorylation, increased LIMK2/cofilin phosphorylation, and increased protein expression of fibronectin, compared to Group S. In all three treatment groups, erectile responses, protein expression of fibronectin, and SM/collagen ratio were improved. Group I + L + U showed greater improvement in erectile response than Group I + L. SM content and apoptotic index in Groups I + U and I + L + U were improved compared to those in Group I. However, Group I + L did not show a significant improvement in SM content or apoptotic index. The number of phospho-LIMK2-positive fibroblasts was normalized in Groups I + L and I + L + U, but not in Group I + U. Akt/eNOS phosphorylation was improved in Groups I + U and I + L + U, but not in Group I + L. LIMK2/cofilin phosphorylation was improved in Groups I + L and I + L + U, but not in Group I + U. Our data indicate that combined treatment of LIMK2i and PDE5i immediate after CN injury could improve erectile function by improving cavernous apoptosis or eNOS phosphorylation and suppressing cavernous fibrosis. Rectification of Akt/eNOS and LIMK2/cofilin pathways appears to be involved in their improvement.
机译:我们旨在确定LIM激酶2抑制剂(LIMK2i)和磷酸二酯酶5型抑制剂(PDE5i)的组合能否通过抑制海绵状神经挤压损伤(CNCI)大鼠模型来恢复勃起功能,从而抑制海绵状纤维化和改善海绵状细胞凋亡。将70只12周大的Sprague–Dawley大鼠平均分为以下五组:(1)假手术(S组),(2)CNCI(I组),(3)每天腹膜内给药10.0 mg的CNCI kg −1 LIMK2i(I + L组),(4)每天口服20.0 mg kg −1 udenafil,PDE5i(I + U组)和(5 )联合给药10.0 mg kg -1 LIMK2i和20.0 mg kg -1 udenafil(I + L + U组)。 I + L,I + U和I + L + U组中的大鼠在接受CNCI后分别接受了2周的治疗。手术后2周,使用电刺激评估勃起反应。处理阴茎组织用于组织学研究和蛋白质印迹。第一组显示出较低的腔内压力(ICP)/平均动脉压(MAP),较低的曲线下面积(AUC)/ MAP,α平滑肌(SM)肌动蛋白的免疫组织化学染色降低,凋亡指数较高,SM /胶原蛋白比率较低与S组相比,纤溶酶的磷酸化,LIMK2阳性成纤维细胞增加,蛋白激酶B /内皮一氧化氮合酶(Akt / eNOS)磷酸化减少,LIMK2 / cofilin磷酸化增加以及纤连蛋白的蛋白质表达增加。在所有三个治疗组中,勃起响应,纤连蛋白的蛋白表达和SM /胶原蛋白比得到改善。 I + L + U组比I + L组表现出更大的勃起反应改善。I+ U组和I + L + U组的SM含量和凋亡指数均比I组有所改善。没有显示出SM含量或凋亡指数的显着改善。在I + L组和I + L + U组中磷酸化LIMK2阳性成纤维细胞的数量正常化,但在I + U组中未标准化。在I + U组和I + L + U组中Akt / eNOS磷酸化得到改善,但是在I + L和I + L + U组中,LIMK2 / cofilin的磷酸化得到改善,但在I + U组中没有改善。我们的数据表明,CN损伤后即刻联合使用LIMK2i和PDE5i可改善勃起。通过改善海绵状细胞凋亡或eNOS磷酸化并抑制海绵状纤维化发挥功能。 Akt / eNOS和LIMK2 / cofilin途径的矫正似乎与它们的改善有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号